Is percutaneous microwave ablation of liver tumor safe for patients with renal dysfunction
| Autor: | Pei Zhou, Xiaoling Yu, Yang Wang, Ping Liang, He Ren, Baowei Dong, Cun Liu |
|---|---|
| Rok vydání: | 2011 |
| Předmět: |
Adult
Male medicine.medical_specialty Percutaneous Liver tumor medicine.medical_treatment Urology Renal function Kidney Kidney Function Tests Serum urea chemistry.chemical_compound Humans Urea Medicine Radiology Nuclear Medicine and imaging Renal replacement therapy Ultrasonography Doppler Color Microwaves Aged Retrospective Studies Creatinine business.industry Liver Neoplasms Microwave ablation Significant difference General Medicine Middle Aged medicine.disease Magnetic Resonance Imaging Surgery Treatment Outcome chemistry Catheter Ablation Female business |
| Zdroj: | European Journal of Radiology. 79:e103-e107 |
| ISSN: | 0720-048X |
| DOI: | 10.1016/j.ejrad.2011.04.050 |
| Popis: | Purpose To determine the safety of percutaneous microwave ablation of primary and metastatic liver tumor for patients with renal dysfunction. Materials and methods Fifty primary and metastatic liver tumors in 23 patients with renal dysfunction were retrospectively reviewed at our institution. Renal function was determined by measuring serum creatinine and serum urea before MWA as baseline, within 1 week and at last follow-up. The mean creatinine was 1.69 ± 0.32 mg/dL, 1.71 ± 0.33 mg/dL, and 1.71 ± 0.26 mg/dL respectively, there was not a statistically significant difference between baseline and at last follow-up ( P = 0.26). The mean serum urea was 52.52 ± 6.48 mg/dL, 56.55 ± 14.72 mg/dL, and 57.90 ± 16.39 mg/dL respectively, there was not a statistically significant difference between baseline and within 1 week ( P = 0.119), between within baseline and at last follow-up ( P = 0.090). At the last follow-up examination, all patients had adequately functioning kidneys and did not require any form of renal replacement therapy. This is a small retrospectively study including highly selected patients treated. Therefore, further study should to determine the safety of percutaneous MWA for patients with renal dysfunction in the future. Conclusions Percutaneous microwave ablation of primary and metastatic liver tumor is no adverse influence on renal function for patients with renal dysfunction in this preliminary series, which can be a minimally invasive alternative therapy. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect